Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02953873 · ClinicalTrials.gov registry record · Phase 4
Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients
A Phase 4 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT02953873 is a Phase 4 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 25 participants.
The verdict
NCT02953873, a Phase 4 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
Compare the difference in dose-normalized trough and total daily dose necessary to reach the steady state therapeutic goal after conversion from tacrolimus IR to Astagraf XL® in African American kidney transplant recipients.
Interventions
- DRUG Prednisone
- DRUG Mycophenolate mofetil
- DRUG Mycophenolate Sodium
- DRUG Tacrolimus Extended Release Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-05-05 |
| Est. Completion | 2018-12-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02953873
The ClinicalTrials.gov registry entry for NCT02953873 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Prednisone is the first listed.
NCT02953873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02953873 about?
NCT02953873 is a clinical study titled "Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients". Compare the difference in dose-normalized trough and total daily dose necessary to reach the steady state therapeutic goal after conversion from tacrolimus IR to Astagraf XL® in African American kidney transplant recipients.
What is the current status of trial NCT02953873?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2017-05-05. Estimated completion is 2018-12-14.
What interventions are being tested in trial NCT02953873?
The interventions under investigation include: Prednisone (DRUG), Mycophenolate mofetil (DRUG), Mycophenolate Sodium (DRUG), Tacrolimus Extended Release Capsule (DRUG).
Who is sponsoring clinical trial NCT02953873?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.